Core Viewpoint - Zhengye Biology (ZYBT) experienced an 8.68% increase in stock price, reaching $5.76 per share, with a total market capitalization of $273 million as of August 5 [1] Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company was 11.31 million RMB, showing a significant year-on-year decline of 64.04% [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨8.68%，报5.76美元/股，总市值2.73亿美元